Supply of Active Substance: Mitotane 500 mg
About This Opportunity
TranslatedThis tender is for the supply of the active substance Mitotane in a dosage of 500 mg. Mitotane is primarily used in the treatment of adrenal cortex carcinoma and is essential for the management of certain types of cancer. The procurement aims to ensure a consistent and reliable supply of this critical medication to healthcare providers. Key requirements for bidders may include the ability to meet specific quality standards, compliance with regulatory guidelines, and the capacity to deliver the product within stipulated timelines. The tender is open to pharmaceutical manufacturers and suppliers who can demonstrate their capability in providing high-quality active pharmaceutical ingredients. Interested parties should prepare to submit their proposals, including detailed information about their production processes, quality control measures, and previous experience in supplying similar substances. The location for delivery and the expected duration of the contract may also be specified in the tender documents. This procurement is crucial for maintaining effective treatment options for patients requiring Mitotane, thereby contributing to improved health outcomes in the oncology sector.
This is a supplies contract in the health and medical services, information and communication technology and trade and industry sectors, with a focus on Pharmaceuticals, Manufacturing and Quality Standards. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 40,036.
Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: PortugueseThis tender pertains to the supply of the active pharmaceutical ingredient Mitotano at a concentration of 500 mg, aimed at enhancing healthcare provisions in Portugal. The procurement falls under the category of pharmaceutical supplies, specifically involving the provision of essential medicines for therapeutic use.
Mitotano is primarily utilized in the treatment of adrenocortical carcinoma, making it a critical component in oncology medication regimens. The contracting authority, although not explicitly stated, is expected to be affiliated with a public health institution or government agency responsible for pharmaceutical procurement in Portugal, as indicated by the centralization of public contracts on the BASE portal.
Bidders are typically required to demonstrate compliance with regulatory standards set forth by the European Medicines Agency (EMA) and the Portuguese National Authority of Medicines and Health Products (INFARMED). This includes providing evidence of Good Manufacturing Practices (GMP) certification, quality assurance protocols, and documentation that ensures the safety and efficacy of the supplied substance.
Furthermore, interested suppliers should prepare to submit detailed technical specifications, pricing proposals, and delivery timelines, along with any relevant certifications or licenses to operate within the pharmaceutical sector. The tender process emphasizes transparency and competitiveness, encouraging qualified pharmaceutical manufacturers and distributors to participate in this essential procurement initiative aimed at improving patient care through reliable access to critical medications.
Data provenance
This notice is sourced from base_gov_pt and was originally published on February 26, 2026. Last refreshed 8 days ago. Original language: Portuguese. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Unidade Local de Saúde de Matosinhos, EPE
Unidade Local de Saúde de Matosinhos, EPE has issued 63 procurement notices on BidsFactory, including 0 currently open and 39 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Information & Communication Technology. All notices are published for Portugal. Notices are distributed via base_gov_pt and TED - Tenders Electronic Daily (EU). Most recent publication: June 12, 2026.
Frequently asked questions about this tender
Is this tender still open?
No — the contract has already been awarded to ESTEVE PHARMACEUTICALS - LABOR FARMACEUTICO LDA. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by Unidade Local de Saúde de Matosinhos, EPE in Portugal. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
What is the estimated budget?
The estimated contract value is Up to €40,036. Bidders should ensure their proposals are consistent with this range and account for any local taxes and contract execution costs.
Where will the contract be performed?
The contract is for delivery in Portugal. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit base_gov_pt to access the full notice, required documents, and submission instructions provided by the contracting authority.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.